AMIX

Autonomix Medical, Inc. operates as a medical device company developing innovative technologies for sensing and treating disorders related to the nervous system. Headquartered in Simi Valley, California, the company focuses on advancing its proprietary platform technologies that target the autonomic nervous system to diagnose and treat a range of diseases and conditions. The company's lead product candidate is the AXNN-1 peripheral nerve stimulation system, designed to provide long-term pain relief through neurostimulation therapy. Autonomix also develops the AXNN-2 system, which combines neural sensing and ablation capabilities for applications in cardiovascular and oncological procedures. The technology aims to enable physicians to identify and modulate specific nerve pathways with greater precision than existing methods. As a clinical-stage company, Autonomix conducts research and development activities while advancing its products through regulatory pathways. The company pursues strategic partnerships and collaborations to support its development programs and expand potential applications of its technology platform. Autonomix trades on the Nasdaq Capital Market and maintains operations focused on bringing its neuroscience-based medical devices from development through commercialization. The company targets markets including chronic pain management, cardiovascular disease treatment, and cancer therapy, where autonomic nervous system modulation may provide therapeutic benefits.